#obesity

2개의 글

May 13, 2026

VKTX Viking Therapeutics Stock Outlook 2026: VK2735 Obesity Drug vs LLY NVO

VKTX Viking Therapeutics 2026. VK2735 obesity Phase 3, oral GLP-1 race vs LLY NVO, VK0214 X-ALD pipeline, M&A optionality and clinical scenarios.

VKTX Viking Therapeutics biotech

May 11, 2026

NVO Novo Nordisk Stock Outlook 2026: GLP-1 Dominance Under Pressure

NVO Novo Nordisk stock outlook for 2026. Wegovy and Ozempic franchise vs Eli Lilly competition, CagriSema REDEFINE trial setback, IRA Medicare drug pricing risk, amycretin pipeline, and three-scenario valuation analysis for US investors.

NVO Novo Nordisk GLP-1